Please assess the completion status of the following clinical trial:

Trial Title: Taxotere Prostate Cancer New Indication Registration Trial in China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven prostate adenocarcinoma~* Androgen independent prostate Cancer S/P orchiectomy and/or LHRH agonist Testosterone \< 50 ng/dl (ie 1.735 nmol/l)~* Documented progressive disease~* Patients should have achieved stable analgesia for 7 days~* Karnofsky Performance Status ≥ 70~* No prior treatment with cytotoxic agent (except estramustine)~* Normal cardiac function must be confirmed by Left ventricular ejection fraction~* Adequate organ function:~  1. Hematology:~     * Neutrophils \> 1.5 x 10\^9/L~    * Hemoglobin \> 10 g/dl. Erythropoietin use is allowed, but red blood cell transfusion to upgrade the hemoglobin level is not allowed~    * Platelets \> 100 x 10\^9/L~ 2. Hepatic function:~     * Total bilirubin \< the upper-normal limit of the institution.~    * Alanine aminotransferase and Aspartate transaminase \< 1.5 times the upper-normal limit of the institution.~ 3. Renal function:~     * Creatinine \< 1.5 times the upper normal limit (ie National Cancer Institution grade \< 1)~* No brain or leptomeningeal metastases~Exclusion Criteria:~* Prior radiotherapy to \>25% of bone marrow (whole pelvic irradiation is not allowed)~* prior cytotoxic chemotherapy, except monotherapy with estramustine~* prior isotope therapy~* history of another cancer within the preceding five year~* symptomatic peripheral neuropathy grade ≥ 2~* other serious illness or medical condition:~  1. Congestive heart failure even if controlled. Previous history of myocardial infarction or angina pectoris within 1 year from study entry, uncontrolled hypertension or uncontrolled arrhythmias.~ 2. Active uncontrolled infection~ 3. Peptic ulcer, unstable diabetes mellitus or other contraindications for the use of corticosteroids.~ 4. Auto-immune disease (lupus, sclerodermia, rheumatoid polyarthritis)~* treatment with any other anti-cancer therapy~* treatment with bisphosphonates~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Docetaxel 75mg/m² intravenously (day 1) every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
- 2 (Type: ACTIVE_COMPARATOR): Mitoxantrone 12mg/m² intravenously every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).